Literature DB >> 17433700

Testicular degeneration in Huntington disease.

Jeremy M Van Raamsdonk1, Zoe Murphy, David M Selva, Reza Hamidizadeh, Jacqueline Pearson, Asa Petersén, Maria Björkqvist, Cameron Muir, Ian R Mackenzie, Geoffrey L Hammond, A Wayne Vogl, Michael R Hayden, Blair R Leavitt.   

Abstract

Huntington disease (HD) is an adult onset, neurodegenerative disorder that results from CAG expansion in the HD gene. Recent work has demonstrated testicular degeneration in mouse models of HD and alterations in the hypothalamic-pituitary-gonadal (HPG) axis in HD patients. Here, we show that HD patients have specific testicular pathology with reduced numbers of germ cells and abnormal seminiferous tubule morphology. In the YAC128 mouse model, testicular degeneration develops prior to 12 months of age, but at 12 months, there is no evidence for decreased testosterone levels or loss of GnRH neurons in the hypothalamus. This suggests that testicular pathology results from a direct toxic effect of mutant huntingtin in the testis and is supported by the fact that huntingtin is highly expressed in the affected cell populations in the testis. Understanding the pathogenesis of HD in the testis may reveal common critical pathways which lead to degeneration in both the brain and testis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17433700     DOI: 10.1016/j.nbd.2007.01.006

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  23 in total

1.  Is Huntington disease a developmental disorder?

Authors:  Sandrine Humbert
Journal:  EMBO Rep       Date:  2010-12       Impact factor: 8.807

Review 2.  Choosing an animal model for the study of Huntington's disease.

Authors:  Mahmoud A Pouladi; A Jennifer Morton; Michael R Hayden
Journal:  Nat Rev Neurosci       Date:  2013-10       Impact factor: 34.870

Review 3.  Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis.

Authors:  C Y Daniel Lee; Jeffrey P Cantle; X William Yang
Journal:  FEBS J       Date:  2013-07-31       Impact factor: 5.542

4.  An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes.

Authors:  Amber L Southwell; Amy Smith-Dijak; Chris Kay; Marja Sepers; Erika B Villanueva; Matthew P Parsons; Yuanyun Xie; Lisa Anderson; Boguslaw Felczak; Sabine Waltl; Seunghyun Ko; Daphne Cheung; Louisa Dal Cengio; Ramy Slama; Eugenia Petoukhov; Lynn A Raymond; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2016-07-04       Impact factor: 6.150

5.  Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.

Authors:  Brett D Dufour; Jodi L McBride
Journal:  Neurobiol Dis       Date:  2018-10-05       Impact factor: 5.996

6.  Environmental enrichment rescues female-specific hyperactivity of the hypothalamic-pituitary-adrenal axis in a model of Huntington's disease.

Authors:  X Du; L Leang; T Mustafa; T Renoir; T Y Pang; A J Hannan
Journal:  Transl Psychiatry       Date:  2012-07-03       Impact factor: 6.222

Review 7.  Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.

Authors:  Pawel M Switonski; Wojciech J Szlachcic; Agnieszka Gabka; Wlodzimierz J Krzyzosiak; Maciej Figiel
Journal:  Mol Neurobiol       Date:  2012-09-04       Impact factor: 5.590

Review 8.  An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity.

Authors:  G Cisbani; F Cicchetti
Journal:  Cell Death Dis       Date:  2012-08-30       Impact factor: 8.469

9.  Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease.

Authors:  Jeffrey B Carroll; Amber L Southwell; Rona K Graham; Jason P Lerch; Dagmar E Ehrnhoefer; Li-Ping Cao; Wei-Ning Zhang; Yu Deng; Nagat Bissada; R Mark Henkelman; Michael R Hayden
Journal:  Mol Neurodegener       Date:  2011-08-19       Impact factor: 14.195

10.  Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.

Authors:  Hilary Moffitt; Graham D McPhail; Ben Woodman; Carl Hobbs; Gillian P Bates
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.